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Multiple sclerosis (MS) features a substantial white matter (WM) pathology in the brain, which
manifests as focal lesions and reduced volume (or atrophy) compared with healthy controls. In
addition, extensive gray matter (GM) atrophy is strongly prevalent in MS and highly clinically
relevant but can be diﬃcult to measure, especially in a clinical setting.1 Recent work has shown
clear patterns of GM atrophy in patients with MS2 that are focused on brain network hubs,
i.e., regions that are strongly connected with the rest of the brain. These areas are important for
cognitive decline and disability progression and include the thalamus3 and other regions
belonging to the default-mode2,4 and motor networks.2 There has been a recent surge of
interest in the thalamus, with some hope that thalamic atrophy and its associated dysfunction
may be a treatment target of especially high potential3 because thalamic atrophy can be
measured relatively easily. The value of including thalamic atrophy as a trial endpoint in clinical
trials with disease-modifying treatment in MS is emerging.5
In this issue of Neurology®, Gaetano et al.6 present their post hoc analysis of 2 randomized
placebo-controlled phase III trials (FTY720 Research Evaluating Eﬀects of Daily Oral Therapy
in Multiple Sclerosis [FREEDOMS] and FREEDOMS II) of ﬁngolimod, a second-line treat-
ment option for MS in most countries. Fingolimod consists of a sphingosine-1-phosphate
receptor modulator that sequesters lymphocytes in lymph nodes, preventing their entry into
the brain. Fingolimod reduces the annual rate of brain volume loss in patients with relapsing-
remitting MS by approximately one-third relative to that in individuals receiving placebo or
intramuscular interferon beta-1a.7 This new analysis of the FREEDOMS and FREEDOMS II
trials describes the eﬀect of ﬁngolimod in reducing regional volume loss, thereby extending and
completing previous reports.
Gaetano et al. conﬁrmed that ﬁngolimod reduces the overall brain volume loss by about one-
third (31.7%) at a clinical dosage of 0.5 mg. In addition, it has an eﬀect on reducing the deep
GM volume loss by 14.5% and the thalamic volume loss by 26.1% over 2 years. No signiﬁcant
eﬀect on cortical atrophy was detected. Baseline T2 lesion volumes predicted thalamic volume
loss. A lower thalamic volume at baseline was associated with disability progression, regardless
of treatment.
The results from this study are an important contribution to the development of MRI endpoints
for clinical trials because they demonstrate that the added value of including regional measures
such as thalamic volume as outcomemeasures in clinical trials is substantial. The addition of such
regional volumes is especially beneﬁcial if they show a faster rate of change than whole-brain
volume loss and their measurement error is relatively small. This study suggests that reanalyses of
existing datasets with newer analysis techniques are attractive and should be pursued.
Themechanism by which ﬁngolimod reduces the volume loss in the deep GM and the thalamus
in MS remains unclear. Lesions within the thalamus are not that common and do not correlate
well with thalamic atrophy,8 suggesting that eﬀects in other compartments such as theWMmay
be the causative factor for thalamic damage. The present article presents additional support for
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this hypothesis; the strong correlation between thalamic
volume loss and baseline T2 lesions suggests that structural
disconnection is the cause of thalamic atrophy. Given that the
thalamus is one of the most important hubs in our brain, the
chance that WM lesions will aﬀect tracts connected to the
thalamus is considerable, inducing a progressive disconnec-
tion syndrome over time. This concept of a network-based
neurodegeneration may explain the early presentation of
thalamic atrophy,3 whereas the apparent later involvement of
cortical areas and the subsequent acceleration of GM atrophy
in progressiveMS9 may be the result of a further exhaustion of
the brain network, leading to an eventual network collapse.10
This study is one of the ﬁrst to show a GM compartment–
speciﬁc treatment eﬀect but should nonetheless be treated with
caution. The primary drawback of the study lies in the use of
cross-sectional techniques to determine longitudinal atrophy
rates, which is an important problem likely to be alleviated with
newer longitudinal analysis tools currently being developed. In
addition, there is the lack of regional cortical GM measure-
ments and an absolute increase in WM volume in ﬁngolimod-
treated patients only, which may be due to a bias in the imaging
analysis algorithm or to biological factors.
Some key unanswered questions remain. Is an early network
disconnection indeed the primary cause of thalamic neuro-
degeneration in MS? Will this thalamic damage lead to
a subsequent cortical network collapse (with atrophy on
MRI) and acceleration of GM atrophy over time? The pos-
sibility of slowing down neurodegeneration inMS is therefore
of high interest and novel. Longitudinal imaging studies are
needed to better understand the underlying mechanisms
leading to thalamo-cortical neurodegeneration in MS and to
identify whether thalamic atrophy is a suitable trial endpoint
to be added to whole-brain atrophy measures.
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